Hong Kong suspends BioNTech vaccines amid packaging defects
BioNTech will conduct a probe at its production facilities, while Hong Kong will examine whether the logistics process caused the defects
26 March 2021 - 09:26
Hong Kong and Macau temporarily suspended Covid-19 vaccines manufactured by BioNTech because of a packaging defect, dealing a blow to inoculation drives seen as key to reviving the cities’ pandemic-battered economies.
BioNTech and Shanghai Fosun Pharmaceutical Group, which has the rights to market the mRNA vaccine across mainland China, Hong Kong, Macau and Taiwan, have initiated an investigation into the issue, according to statements from the Hong Kong and Macau governments. There is no reason to believe there is a safety risk for the population, BioNTech and Fosun said...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.